2019 IPO
Axcella Stock
Axcella is a biotechnology company providing therapeutics development solutions.
Sign up today and learn more about Axcella Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Axcella Stock
Axcella Health is pioneering revolutionary new medicines with a focus on amino acid homeostasis. The company has discovered more than 2,000 diseases with amino acid imbalances and developed a systems pharmacology approach to restore health at the cellular level. Axcella’s proprietary platform is clinically validated across several indication areas, with clinical-stage candidates in muscle, neurodegenerative and liver conditions. Axcella is led by a team with a strong track record of leaving a lasting impact on the therapeutic landscape through the development of novel products.
Funding History
October 2013 | $10.8M |
---|---|
December 2013 | $0 |
May 2015 | $39.0M |
February 2016 | $42.5M |
November 2018 | $59.0M |
Management
Founder
David Berry
Senior Vice President and Chief Medical Officer
Christopher Wright
CFO
Jeff Moore
President and Chief Executive Officer
William Hinshaw
President of R&D and Chief Scientific Officer
Peter Mueller
Co-Founder
Geoffrey von Maltzahn
Principal Research Fellow
Eugenio Ferrari
VP, Research
Michael Hamill